Forward Looking Statements Certain statements in this release or presentation, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or changes to our credit rating; (4) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to factors outside of our control, such as natural disasters, acts of war or terrorism, or disease outbreaks; (5) the ability to successfully manage cost fluctuations and pressures, including prices of commodities and raw materials, and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third party information and operational technology systems, networks and services, and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage uncertainties related to changing political conditions (including the United Kingdom’s exit from the European Union) and potential implications such as exchange rate fluctuations and market contraThe Procter & Gamble Company Regulation G Reconciliation of Non-GAAP Measures
In accordance with the SEC's Regulation G, the following provides definitions of the non-GAAP measures used in Procter & Gamble's January 20, 2021 earnings call, associated slides, and other materials and the reconciliation to the most closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e. trends excluding non-recurring or unusual items) and results and provide a supplemental measure of year-on-year results. The non-GAAP measures described below are used by Management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors as they provide supplemental information about business performance and provide investors a view of our business results through the eyes of Management. Certain of these measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not intended to be considered by the user in place of the related GAAP measure, but rather as supplemental information to our business results. These non-GAAP measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted. The Company is not able to reconcile its forward-looking non-GAAP cash flow and effective tax rate measures because the Company cannot predict the timing and amounts of discrete items such as acquisition and divestitures, which could significantly impact GAAP results.
The measures provided are as follows:
1. | Organic sales growth — page 3 |
2. | Core EPS and currency-neutral Core EPS — page 5 |
3. | Core gross margin and currency-neutral Core gross margin – page 7 |
4. | Core operating profit margin and currency-neutral Core operating profit margin — page 7 |
5. | Adjusted free cash flow productivity — page 8 |
Organic sales growth*: Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures, the impact from the July 1, 2018 adoption of new accounting standards for “Revenue from Contracts with Customers”, the impact from India Goods and Services Tax changes (which were effective on July 1, 2017), the impact of Venezuela deconsolidation in 2016 and foreign exchange from year-over-year comparisons. Management believes this measure provides investors with a supplemental understanding of underlying sales trends by providing sales growth on a consistent basis.
The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:
• | Incremental restructuring: The Company has historically had an ongoing level of restructuring activities. Such activities have resulted in ongoing annual restructuring related charges of approximately $250 - $500 million before tax. Since 2012, the Company has had a strategic productivity and cost savings initiative that resulted in incremental restructuring charges. The adjustment to Core earnings includes only the restructuring costs above what we believe are the normal recurring level of restructuring costs. In fiscal 2021 and onwards, the Company expects to incur restructuring costs within our historical ongoing level. |
• | Gain on Dissolution of the PGT Healthcare Partnership: The Company finalized the dissolution of our PGT Healthcare partnership, a venture between the Company and Teva Pharmaceuticals Industries, Ltd (Teva) in the OTC consumer healthcare business, in the quarter ended September 30, 2018. The transaction was accounted for as a sale of the Teva portion of the PGT business; the Company recognized an after-tax gain on the dissolution of $353 million. |
• | Shave Care Impairment: In the fourth quarter of fiscal 2019, the company recognized a one-time, non-cash, after-tax charge of $8.0 billion ($8.3 billion before tax) to adjust the carrying values of the Shave Care reporting unit. This was comprised of a before and after-tax impairment charge of $6.8 billion related to goodwill and an after-tax impairment charge of $1.2 billion ($1.6 billion before tax) to reduce the carrying value of the Gillette indefinite-lived intangible assets. |
• | Anti-dilutive Impacts: The Shave Care impairment charges caused certain equity instruments that are normally dilutive (and hence normally assumed converted or exercised for the purposes of determining diluted net earnings per share) to be anti-dilutive. Accordingly, for U.S. GAAP diluted earnings per share, these instruments were not assumed to be concerted or exercised. Specifically, in the fourth quarter and total fiscal 2019, the weighted average outstanding preferred shares were not included in the diluted weighted average common shares outstanding. Additionally, in the fourth quarter of fiscal 2019, none of our outstanding share-based equity awards were included in the diluted weighted average common shares outstanding. As a result of the non-GAAP Shave Care impairment adjustment, these instruments are dilutive for non-GAAP earnings per share. |
• | Early debt extinguishment charges: In the three months ended December 31, 2020, the company recorded after tax charges of $427 million ($512 million before tax), due to early extinguishment of certain long-term debt. These charges represent the difference between the reacquisition price and the par value of the debt extinguished. |
• | Transitional Impact of U.S. Tax Act: In December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Act") that resulted in net transitional charges. The adjustment to Core earnings only includes this transitional impact. It does not include the ongoing impacts of the lower U.S. statutory rate on the respective years' earnings. |
We do not view the above items to be part of our sustainable results, and their exclusion from core earnings measures provides a more comparable measure of year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation. Management views the following non-GAAP measures as useful supplemental measures of Company performance and operating efficiency over time.
Core EPS and currency-neutral Core EPS*: Core earnings per share, or Core EPS, is a measure of the Company's diluted net earnings per share from continuing operations adjusted as indicated. Currency-neutral Core EPS is a measure of the Company's Core EPS excluding the incremental current year impact of foreign exchange.
Core gross margin: Core gross margin is a measure of the Company's gross margin adjusted for items as indicated.
Currency-neutral Core gross margin: Currency-neutral Core gross margin is a measure of the Company's Core gross margin excluding the incremental current year impact of foreign exchange.
Core operating profit margin*: Core operating profit margin is a measure of the Company's operating margin adjusted for items as indicated.
Currency-neutral Core operating profit margin*: Currency-neutral Core operating profit margin is a measure of the Company's Core operating profit margin excluding the incremental current year impact of foreign exchange.
Free cash flow: Free cash flow is defined as operating cash flow less capital spending. Free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion. Management views free cash flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investment.
Adjusted free cash flow: Adjusted free cash flow is defined as operating cash flow less capital spending and adjustments for items as indicated. Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion. Management views adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investment.
Adjusted free cash flow productivity*: Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings excluding the charges for early debt extinguishment (which are not considered part of our ongoing operations). Management views adjusted free cash flow productivity as a useful measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used by management in making operating decisions, allocating financial resources and for budget planning purposes. The Company's long-term target is to generate annual free cash flow productivity at or above 90 percent.
* Measure is used to evaluate senior management and is a factor in determining their at-risk compensation.
1. Organic sales growth:
Three Months Ended December 31, 2020 | Net Sales Growth | | Foreign Exchange Impact | | Acquisition & Divestiture Impact/Other* | | Organic Sales Growth |
Beauty | 6% | | -1% | | -% | | 5% |
Grooming | 5% | | 1% | | -% | | 6% |
Health Care | 9% | | -% | | -% | | 9% |
Fabric Care & Home Care | 7% | | -% | | -% | | 12% |
Baby, Feminine & Family Care | 4% | | -% | | -% | | 6% |
Total P&G | 8% | | -% | | -% | | 8% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.
Six Months Ended December 31, 2020 | Net Sales Growth | | Foreign Exchange Impact | | Acquisition & Divestiture Impact/Other* | | Organic Sales Growth |
Total P&G | 8% | | 1% | | -% | | 9% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.
Organic Sales
Calendar Year 2019
Total Company | Net Sales Growth | | Foreign Exchange Impact | | Acquisition & Divestiture Impact/Other* | | Organic Sales Growth |
Calendar Year 2019 | 4% | | 3% | | (1)% | | 6% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures for all periods, the impact from the July 1, 2018 adoption of new accounting standards for "Revenue from Contracts with Customers" and rounding impacts necessary to reconcile net sales to organic sales.
Organic Sales
Calendar Year 2020
Total Company | Net Sales Growth | | Foreign Exchange Impact | | Acquisition & Divestiture Impact/Other* | | Organic Sales Growth |
Calendar Year 2020 | 6% | | 1% | | 1% | | 8% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures for all periods and rounding impacts necessary to reconcile net sales to organic sales.
Organic Sales
Prior Quarters
Total Company | Net Sales Growth | | Foreign Exchange Impact | | Acquisition/ Divestiture Impact/Other* | | Organic Sales Growth |
JAS 2019 | 7% | | 2% | | (2)% | | 7% |
OND 2019 | 5% | | 1% | | (1)% | | 5% |
JFM 2020 | 5% | | 2% | | (1)% | | 6% |
AMJ 2020 | 4% | | 3% | | (1)% | | 6% |
JAS 2020 | 9% | | 1% | | (1)% | | 9% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.
Organic Sales
Prior Quarters Beauty
Total Beauty | Net Sales Growth | | Foreign Exchange Impact | | Acquisition/ Divestiture Impact/Other* | | Organic Sales Growth |
OND 2015 | (10)% | | 7% | | 4% | | 1% |
JFM 2016 | (8)% | | 5% | | 4% | | 1% |
AMJ 2016 | (5)% | | 3% | | 3% | | 1% |
JAS 2016 | (1)% | | 2% | | 2% | | 3% |
OND 2016 | (1)% | | 2% | | 2% | | 3% |
JFM 2017 | (2)% | | 1% | | 2% | | 1% |
AMJ 2017 | 2% | | 2% | | 1% | | 5% |
JAS 2017 | 5% | | -% | | -% | | 5% |
OND 2017 | 10% | | (1)% | | -% | | 9% |
JFM 2018 | 10% | | (5)% | | -% | | 5% |
AMJ 2018 | 10% | | (3)% | | -% | | 7% |
JAS 2018 | 5% | | 3% | | (1)% | | 7% |
OND 2018 | 4% | | 4% | | -% | | 8% |
JFM 2019 | 4% | | 5% | | -% | | 9% |
AMJ 2019 | 3% | | 5% | | -% | | 8% |
JAS 2019 | 8% | | 2% | | -% | | 10% |
OND 2019 | 7% | | 1% | | -% | | 8% |
JFM 2020 | (1)% | | 2% | | -% | | 1% |
AMJ 2020 | -% | | 4% | | (1)% | | 3% |
JAS 2020 | 7% | | 1% | | (1)% | | 7% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures for all periods, the impact from the July 1, 2018 adoption of new accounting standards for "Revenue from Contracts with Customers", the impact of India Goods and Services Tax implementation in FY 2018, the impact of Venezuela deconsolidation in 2016 and rounding impacts necessary to reconcile net sales to organic sales.
Organic Sales
Guidance
Total Company | | Net Sales Growth | | Combined Foreign Exchange & Acquisition/Divestiture Impact/Other* | | Organic Sales Growth |
FY 2021 (Estimate) | | +5% to +6% | | - | | +5% to +6% |
* Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to organic sales.
2. Core EPS and currency-neutral Core EPS:
| Three Months Ended December 31 |
| 2020 | | 2019 |
Diluted Net Earnings Per Share | $1.47 | | $1.41 |
Incremental Restructuring | | | 0.01 |
Early Debt Extinguishment | 0.16 | | |
Rounding | 0.01 | | |
Core EPS | $1.64 | | $1.42 |
Percentage change vs. prior period | 15% | | |
Currency Impact to Earnings | 0.03 | | |
Currency-Neutral Core EPS | $1.67 | | |
Percentage change vs. prior period Core EPS | 18% | | |
Note – All reconciling items are presented net of tax. Tax effects are calculated consistent with the nature of the underlying transaction.
| Six Months Ended December 31 |
| 2020 | | 2019 |
Diluted Net Earnings Per Share | $3.10 | | $2.77 |
Incremental Restructuring | | | 0.02 |
Early Debt Extinguishment | 0.16 | | |
Rounding | 0.01 | | |
Core EPS | $3.27 | | $2.79 |
Percentage change vs. prior period | 17% | | |
Currency Impact to Earnings | 0.07 | | |
Currency-Neutral Core EPS | $3.34 | | |
Percentage change vs. prior period Core EPS | 20% | | |
Note – All reconciling items are presented net of tax. Tax effects are calculated consistent with the nature of the underlying transaction.
Core EPS
Calendar Year 2019
| Twelve Months Ended December 31 |
| 2019 | | 2018 |
Diluted Net Earnings Per Share | $1.78 | | $4.11 |
Incremental Restructuring | 0.10 | | 0.24 |
Transitional Impacts of U.S. Tax Reform | | | (0.01) |
Gain on Dissolution of PGT Partnership | | | (0.13) |
Early Debt Extinguishment | | | 0.09 |
Shave Care Impairment | 3.02 | | |
Anti-Dilutive Impact | 0.04 | | |
Core EPS | $4.94 | | $4.30 |
Percentage change vs. prior period | 15% | | |
Currency Impact to Earnings | 0.20 | | |
Rounding | 0.01 | | |
Currency-Neutral Core EPS | $5.15 | | |
Percentage change vs. prior period Core EPS | 20% | | |
Note – All reconciling items are presented net of tax. Tax effects are calculated consistent with the nature of the underlying transaction.
Core EPS
Prior Quarters
| JAS 19 | JAS 18 | OND 19 | OND 18 | JFM 20 | JFM 19 | AMJ 20 | AMJ 19 | JAS 20 | JAS 19 |
Diluted Net Earnings Per Share attributable to P&G | $ 1.36 | $ 1.22 | $ 1.41 | $1.22 | $1.12 | $1.04 | $1.07 | $(2.12) | $1.63 | $1.36 |
Incremental Restructuring | 0.01 | 0.03 | 0.01 | 0.03 | 0.05 | 0.02 | 0.09 | 0.06 | | 0.01 |
Gain on Dissolution of PGT Partnership | | (0.14) | | | | | | | | |
Shave Care Impairment | | | | | | | | 3.02 | | |
Anti-dilutive Impacts | | | | | | | | 0.14 | | |
Rounding | | 0.01 | | | | | | | | |
Core EPS | $ 1.37 | $ 1.12 | $1.42 | $1.25 | $1.17 | $1.06 | $1.16 | $1.10 | $1.63 | $1.37 |
Percentage change vs. prior period | 22% | | 14% | | 10% | | 5% | | 19% | |
Currency Impact to Earnings | 0.02 | | 0.02 | | 0.05 | | 0.06 | | 0.04 | |
Currency-Neutral Core EPS | $1.39 | | $1.44 | | $1.22 | | $1.22 | | $1.67 | |
Percentage change vs. prior period Core EPS | 24% | | 15% | | 15% | | 11% | | 22% | |
Note – All reconciling items are presented net of tax. Tax effects are calculated consistent with the nature of the underlying transaction
Core EPS
Guidance
Total Company | Diluted EPS Growth | Impact of Incremental Non-Core Items* | Core EPS Growth |
FY 2021 (Estimate) | +8% to +10% | - | +8% to +10% |
* Includes net impact of prior year incremental non-core restructuring charges and early debt extinguishment charges in FY2021.
3. Core gross margin:
| Three Months Ended December 31 |
| 2020 | 2019 |
Gross Margin | 53.1% | 51.4% |
Incremental Restructuring | | 0.2% |
Core Gross Margin | 53.1% | 51.6% |
Basis point change vs. prior year Core margin | 150 | |
Currency Impact to Margin | 0.5% | |
Currency-Neutral Core Gross Margin | 53.6% | |
Basis point change vs prior year Core margin | 200 | |
4. Core operating profit margin:
| Three Months Ended December 31 |
| 2020 | 2019 |
Operating Profit Margin | 27.2% | 24.6% |
Incremental Restructuring | | 0.1% |
Core Operating Profit Margin | 27.2% | 24.7% |
Basis point change vs. prior year Core margin | 250 | |
Currency Impact Margin | 0.6% | |
Currency-Neutral Core Operating Profit Margin | 27.8% | |
Basis point change vs. prior year Core Margin | 310 | |
5. Adjusted free cash flow productivity (dollar amounts in millions):
Three Months Ended December 31, 2020 |
Operating Cash Flow | Capital Spending | Free Cash Flow | Net Earnings | Early Debt Extinguishment Charges | Net Earnings Excluding Adjustments | Adjusted Free Cash Flow Productivity |
$5,424 | $(567) | $4,857 | $3,887 | $427 | $4,314 | 113% |
Six Months Ended December 31, 2020 |
Operating Cash Flow | Capital Spending | Adjustment* | Adjusted Free Cash Flow | Net Earnings | Early Debt Extinguishment Charges | Net Earnings Excluding Adjustments | Adjusted Free Cash Flow Productivity |
$10,163 | $(1,417) | $225 | $8,971 | $8,195 | $427 | $8,622 | 104% |
*Adjustment to free cash flow is the tax payments for the transitional tax resulting from the U.S. Tax Act.
Twelve Months Ended December 31, 2019 |
Operating Cash Flow | Capital Spending | Adjustments* | Adjusted Free Cash Flow | Net Earnings | Adjustments to Net Earnings** | Adjusted Net Earnings | Adjusted Free Cash Flow Productivity |
$16,201 | $(3,250) | $215 | $13,166 | $4,899 | $7,978 | $12,877 | 102% |
*Adjustments to free cash flow include tax payments for the transitional tax resulting from the U.S. Tax Act and tax payments related to the Merck OTC Consumer Healthcare acquisition.
**Adjustments to Net Earnings relate to the Shave Care Impairment charge.
ction; (13) the ability to successfully manage regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition, intellectual property, labor and employment, antitrust, data protection, tax, environmental, and accounting and financial reporting) and to resolve pending matters within current estimates; (14) the ability to manage changes in applicable tax laws and regulations including maintaining our intended tax treatment of divestiture transactions; (15) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting the delivery of base business objectives; (16) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes, while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; and (17) the ability to successfully manage the demand, supply, and operational challenges associated with a disease outbreak, including epidemics, pandemics, or similar widespread public health concerns (including the novel coronavirus, COVID-19, outbreak). For additional information concerning factors that could cause actual results and events to differ materially from those projected herein, please refer to our most recent 10-K/A, 10-Q and 8-K reports.